KMT2A-REARRANGED ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE

Clinical trials for KMT2A-REARRANGED ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE explained in plain language.

Never miss a new study

Get alerted when new KMT2A-REARRANGED ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE trials appear

Sign up with your email to follow new studies for KMT2A-REARRANGED ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New combo aims to wipe out stubborn leukemia cells

Disease control Not yet recruiting

This study looks at adding a new drug, revumenib, to standard treatment for people with a specific genetic type of leukemia (KMT2A-translocation) that still has traces of disease after initial therapy. About 90 adults and children will be randomly assigned to get either the usual…

Matched conditions: KMT2A-REARRANGED ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE

Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control

Last updated Jun 16, 2026 12:50 UTC

KMT2A-REARRANGED ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE

Get alerted when new KMT2A-REARRANGED ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE trials appear

New combo aims to wipe out stubborn leukemia cells